Seal and logotype of Brandeis University The Heller School logo

Recent Conferences

June 13, 2018

Paying for the Next Generation of Innovative Therapies

Prescription drug pricing has received considerable attention following widely publicized decisions of some firms to charge seemingly exorbitant prices for their products. One area of concern are drugs that have not proven to be cost-effective yet have market demand and lack competition. A second area are new medicines that are extremely expensive yet cost-effective. Examples include new treatments for Hepatitis-C, and new gene therapies. Such therapies with very high up-front costs and long-term benefits pose a challenge for payers. In addition to the initial budget impact, payers stand to lose much of the long-term benefit when patients switch health plans. This may lead to adoption of policies that limit patient access to these therapies. This Forum will examine the challenges of paying for the next generation of innovative therapies. We will begin with an assessment of the pharmaceutical pipeline and potential budget impacts of new drugs coming to market over the next five years. We will then discuss the potential for drug firms to expand the use of value-based pricing when setting launch prices. Next, we will examine the growing use of outcome-based contracts and the potential of such contracts focusing on individual patient response to high price therapies. Finally, we will discuss possible models for financing cost-effective therapies with very high upfront costs.

Speakers Include:   
Stuart Altman, Ph.D., Professor of National Health Policy, Brandeis University  
Steven Miller MD, MBA, Chief Medical Officer, Express Scripts
Michael Sherman MD, Chief Medical Officer, Harvard Pilgrim Healthcare 
Patrick Smith, PharmaD, Director, Clinical Pipeline Services, CVS Health 
Sarah Emond, MPP, Chief Operating Officer, ICER 
Anna Kaltenboeck MA, Program Director, Drug Pricing Lab at Memorial Sloan Kettering 
Jonathan Darrow, S.J.D., LL.M, JD, MBA, Harvard Medical School Program on Regulation, Therapeutics and Law
Colleen Rye, Ph.D., Director, FasterCures
Jason Spangler MD, Executive Director of Value, Quality, & Medical Policy, Amgen
Kristin Viswanathan Wolff, Director, Global Government Affairs and Public Policy, bluebird bio